---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-001993"
form_type: "8-K"
ticker: "SBFM"
cik: "0001402328"
company_name: "Sunshine Biopharma Inc."
filed_at: "2024-04-01T23:59:59+00:00"
generated_at: "2026-06-04T04:25:23.098985+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sunshine Biopharma reports 2023 sales $24.1M, loss per share improves to -$0.19

## Summary
- Sales grew to $24,092,787 in 2023 from $4,345,603 in 2022; average quarter-over-quarter growth of 14%.
- Net loss narrowed to $4,506,044 from $26,744,440; loss per share improved to -$0.19 from -$1.76.
- Gross profit rose to $8,339,171 from $1,696,575; G&A expenses reduced to $13.1M from $28.7M.
- Completed $5M private placement; repurchased 513,723 shares for $541,143.
- Two proprietary drugs advanced to animal testing; IND-enabling studies for Adva-27a halted in November 2023.

## SEC filing metadata
- accession: 0001683168-24-001993
- form_type: 8-K
- ticker: SBFM
- cik: 0001402328
- company_name: Sunshine Biopharma Inc.
- filed_at: 2024-04-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1402328/000168316824001993/0001683168-24-001993-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1402328/000168316824001993/sunshine_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-001993
- JSON: https://secwatch.observer/filing/0001683168-24-001993.json
- Plain text: https://secwatch.observer/filing/0001683168-24-001993.txt

## Key facts
- Earnings Releases
  Sunshine Biopharma Inc. reported the fiscal year ended December 31, 2023 results: revenue $ 24,092,787, net income $ 4,506,044, EPS negative $0.19 per share.
  - Period: the fiscal year ended December 31, 2023
  - Revenue: $ 24,092,787
  - Net income: $ 4,506,044
  - EPS: negative $0.19 per share
  - Result: reported results
  source text: The following are key items contained in the Company’s Income Statement included in the 2023 10-K: 2023 2022 Sales $ 24,092,787 $ 4,345,603 Gross Profit $ 8,339,171 $ 1,696,575 General & Administrative Expenses $ 13,124,470 $ 28,697,325 Goodwill impairment $ – $ 18,326,719 Net Loss $ 4,506,044 $ 26,744,440
  evidence_url: https://www.sec.gov/Archives/edgar/data/1402328/000168316824001993/0001683168-24-001993-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.